Abstract Search

ey0019.11-14 | Weight regulation and endocrine circuits (including interventions) | ESPEYB19

11.14. Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist

A Shoemaker , H Silver , M Buchowski , J Slaughter , J Yanovski , C Elfers , C Roth , MJ Abuzzahab

Ashley.H.Shoemaker@VUMC.org International Journal of Obesity 2022, Epub 2022 Jan 3. doi: 10.1038/s41366-021-01043-6. https://pubmed.ncbi.nlm.nih.gov/34975146/Brief Summary: This double-blind, placebo-controlled trial assessed the efficacy of 36 weeks of GLP1RA treatment with exenatide e...

0 shares

ey0021.11-4 | Interventions for Weight Loss: New Findings | ESPEYB21

11.4. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial

CL Roth , C Scimia , AH Shoemaker , M Gottschalk , J Miller , G Yuan , S Malhotra , MJ Abuzzahab

Brief Summary: This phase 2, open-label, multicenter trial examined the efficacy of setmelanotide, a melanocortin-4 receptor agonist, in patients aged 6 to 40 years with obesity due to hypothalamic injury. Setmelanotide reduced body mass index (BMI) and hunger levels in most participants; 89% achieved a reduction in BMI of at least 5% after 16 weeks. These results indicate that setmelanotide is a promising treatment for hypothalamic obesity.This phase 2 ...

0 shares

ESPE Yearbook of Paediatric Endocrinology

11.14. Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist

11.4. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial

BiosciAbstracts